Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
about
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, anTreatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis.Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faeciumPharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICThe inoculum effect and band-pass bacterial response to periodic antibiotic treatment.Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study.Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis.Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.An in vitro proof-of-principle study of sonobactericide.Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model.
P2860
Q33691841-01E64DB1-E37D-4444-A5F6-888F911D8A6FQ33700022-878AFE60-610B-463D-AAFC-869B89114B7DQ33883648-04AF21CA-03D4-4D19-8AE8-F79CFD0531CFQ33978925-79F2ED32-0616-437F-8CDE-E30026FB5E26Q33980069-2485FD18-6CDA-465F-9F12-A5358FFC333BQ34007865-43FF8EE8-71E9-42B9-873F-5B4A9BA85E8FQ35116133-E04ED5D0-AC7D-41FF-BCAB-0D554BB9F800Q35121233-7351DB3A-CBD7-40F4-B044-C72BEAC0CFF4Q35123155-15B8BB23-F070-45E7-B8A6-B383252C17D4Q35136634-979149D8-0E96-4E5D-B0A5-98089C290BC8Q35136776-E33B7479-2FD4-4F6B-A8A1-BDFF2B30971CQ35138989-14C767E4-8361-49B3-85F9-5DEFA8FDE6E4Q35637864-1A0020BB-4478-463A-8503-20B83619CF7BQ36321625-AA5C425C-84A1-4200-8EDA-0513DE3FA4D9Q36409472-370C91E4-F1B2-4DB5-BE3E-75BB585BE653Q37333049-D40E954C-EB64-4F74-A071-AF9EDCD5850EQ37333096-C83C376B-CBF8-4342-8781-286868A7B972Q37660762-623FF968-C35E-4F4F-8A80-0BB0B725258BQ40345173-B8C7E5E3-B49B-4376-A216-F3A3EFFDB6CBQ40964756-29FC3654-8797-4ED2-926A-F414FB7901EAQ41005454-F48C1014-E011-4799-8C14-D4866CB570D9Q41646436-C8EDDAF1-DF7E-4E54-8212-28DF8B4298BAQ41789314-CED76232-C31D-4FCE-BF90-1E3F09B3AAA6Q50282142-23F3BF71-60C2-456D-9DE3-90812E0232E4Q50991026-67E0A675-388C-4107-9D42-8265FB505B14Q52655242-1F673788-ACFD-4F72-BE9C-FC16B103AAE9
P2860
Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
name
Bactericidal activities of tei ...... dynamic model of endocarditis.
@ast
Bactericidal activities of tei ...... dynamic model of endocarditis.
@en
type
label
Bactericidal activities of tei ...... dynamic model of endocarditis.
@ast
Bactericidal activities of tei ...... dynamic model of endocarditis.
@en
prefLabel
Bactericidal activities of tei ...... dynamic model of endocarditis.
@ast
Bactericidal activities of tei ...... dynamic model of endocarditis.
@en
P2093
P2860
P356
P1476
Bactericidal activities of tei ...... dynamic model of endocarditis.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.9.2034
P407
P577
1994-09-01T00:00:00Z